Wockhardt Limited WOCKPHARMAshare price and chart
Wockhardt closed at ₹2,187.00 on 19 November 2026, up 7.91% on the day. The 52-week range is ₹1,086.70 to ₹2,422.30.
Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.
Loading prices…
Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.Test a strategy on WOCKPHARMA
Real prices, every charge counted. Pick one or write your own.Spent much of the 2010s and early 2020s in financial distress from heavy debt and US FDA manufacturing compliance issues, before re-rating sharply on progress in its long-running program to discover a wholly new antibiotic. On 29 May 2026 its candidate Zaynich (cefepime and zidebactam) received US FDA approval for complicated urinary tract infections, the first new chemical entity fully discovered, developed and commercialised by an Indian pharma company to do so.
Pharma - Anti-Infectives & Novel Drug Research
Generic and branded prescription formulations, biosimilars and insulin products (including Glaritus and Wosulin), active pharmaceutical ingredients, and Zaynich, its newly FDA-approved novel intravenous antibiotic for drug-resistant infections.
Hospitals, pharmacies and healthcare distributors across India, the US and Europe, plus emerging markets in Latin America, Africa, the CIS and Asia; branded generics also reach retail patients directly.
Earns most revenue from selling generic and branded formulations at volume, like most Indian pharma companies. Is now also positioned to earn patent-protected, higher-margin revenue and licensing income from Zaynich, a self-discovered antibiotic aimed at multidrug-resistant bacterial infections.
Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.
EOD 19 NovThe share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Returns and valuationWhat the market pays for this company and how well the business uses its money.
Books to 30 Sept 2026Against its sectorWhere this company ranks among similar companies on each measure.
Pharmaceuticals · 141 peers · mediansWhat the numbers sayShort plain statements about this company's latest figures.
Written by fixed rulesLatest quarterIn the quarter to September 2026 (results filed 2 Nov 2026), sales rose 23.9% from a year earlier to ₹969 cr and profit fell 11.0% to ₹73.0 cr.
- Sales grew 3 years running (₹2,651 cr in FY23 to ₹3,373 cr in FY26).
- Operating margin rose from 2.8% in FY23 to 19.3% in FY26.
- Reported a loss in FY24 and FY25.
- Return on equity stayed under 10% from FY24 to FY26 (highest 4.0%).
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
Share price reaction to resultsWhat the share price did around each recent quarterly result.
Over the last 20 results, the share rose on 6 and fell on 14, and moved by 3% or more on 9.
Q2 FY27: results filed 2 Nov 2026. The share went from its close on 30 Oct 2026 to its close on 3 Nov 2026 -1.74%.
Dividend historyCash the company has paid per share, year by year.
2016 paid ₹10.00 per share, about ₹457 on ₹1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.
What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.
Price only, before dividendsHeld for 20 years this compounded at +9.3% a year. The last twelve months were up +64.4%. Price only, before dividends.
Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.
Who owns itEach line is that holder's share of all shares over the last 6 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.
The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.
Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.
Last 6 monthsKey ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.
Against its sectorPeers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
Revenue and profit, year by yearSales and net profit by financial year or by quarter.
Sales and net profitWhere every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.
FY26In FY26, of every ₹100 of sales it kept ₹5.9 as profit. Other income added ₹3.3.
How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.
Compounded a yearCash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.
Where the cash wentIn FY26 cash rose by ₹105 Cr, after ₹136 Cr spent on plant and equipment.
Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.
| Measure | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Sales growthSales in this financial year against the previous one. | -17.9% | 5.5% | 7.6% | 12.0% |
| Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax. | 2.8% | 0.8% | 13.0% | 19.3% |
| Net marginOf every ₹100 of sales in the year, how much was left as profit after everything. | -23.4% | -16.9% | -1.9% | 5.9% |
| ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money. | -17.0% | -12.9% | -1.4% | 4.0% |
| ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders. | -5.8% | -2.0% | 3.9% | 6.5% |
| Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings. | 0.52x | 0.58x | 0.40x | 0.40x |
| Interest coverHow many times the company's profit before interest could pay its interest bill. | -1.1x | -0.4x | 0.9x | 2.1x |
Each row against this company's own usual level: green better, red worse, grey close to it.
Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.
Pharmaceuticals| Company | What the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality. | How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit. | The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business. | How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money. | How much operating profit the company made on all the money in the business, whether it came from owners or lenders. | Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings. | Of every ₹100 of sales, how much is left as profit after all costs, interest and tax. | How much sales grew in the latest quarter against the same quarter a year earlier. | The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share. |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | 4.56 L cr | 41.6x | 5.1x | 14.7% | 19.1% | 0.03 | 17.8% | +11.9% | 0.84% |
| DIVISLAB Divi's Laboratories Limited | 2.97 L cr | 88.2x | 16.5x | 16.2% | 21.5% | 0.00 | 27.6% | +35.4% | 0.27% |
| TORNTPHARM Torrent Pharmaceuticals Limited | 1.75 L cr | 77.9x | 9.6x | 17.0% | 15.2% | 0.76 | 12.1% | +50.8% | 0.82% |
| LAURUSLABS Laurus Labs Limited | 1.25 L cr | 92.9x | 20.6x | 17.7% | 17.9% | 0.40 | 17.0% | +33.4% | 0.10% |
| ZYDUSLIFE Zydus Lifesciences Limited | 1.20 L cr | 28.9x | 4.3x | 18.3% | 19.9% | 0.44 | 14.1% | +29.2% | 0.08% |
| DRREDDY Dr. Reddy's Laboratories Limited | 1.17 L cr | 41.7x | 3.0x | 11.5% | 13.9% | 0.15 | 8.3% | -1.5% | 0.57% |
| CIPLA Cipla Limited | 1.15 L cr | 39.5x | 3.2x | 11.7% | 16.0% | 0.01 | 10.1% | -2.4% | 0.92% |
| MANKIND Mankind Pharma Limited | 1.09 L cr | 48.4x | 6.2x | 12.4% | 12.9% | 0.30 | 14.7% | +17.3% | 0.00% |
| AUROPHARMA Aurobindo Pharma Limited | 1.04 L cr | 26.2x | 2.6x | 9.9% | 12.8% | 0.21 | 10.8% | +23.9% | 0.39% |
| LUPIN Lupin Limited | 91,403 cr | 17.6x | 3.8x | 26.9% | 28.8% | 0.23 | 17.0% | +11.1% | 0.90% |
| GLENMARK Glenmark Pharmaceuticals Limited | 73,618 cr | 50.7x | 6.6x | 14.1% | 20.4% | 0.08 | 9.2% | -31.3% | 0.10% |
| ALKEM Alkem Laboratories Limited | 61,516 cr | 29.8x | 4.1x | 17.6% | 20.6% | 0.12 | 13.4% | +13.8% | 1.03% |
| BIOCON Biocon Limited | 59,264 cr | 216.5x | 1.7x | 1.1% | 3.0% | 0.41 | 1.9% | +2.2% | 0.14% |
| ABBOTINDIA Abbott India Limited | 54,600 cr | 33.0x | - | - | - | - | 23.0% | +11.0% | 2.55% |
| GLAND Gland Pharma Limited | 54,336 cr | 43.9x | 5.1x | 10.5% | 15.0% | 0.02 | 17.5% | +23.3% | 0.61% |
| IPCALAB IPCA Laboratories Limited | 47,189 cr | 33.6x | 5.4x | 13.2% | 16.6% | 0.06 | 14.2% | +13.8% | 0.32% |
| GLAXO GlaxoSmithKline Pharmaceuticals Limited | 45,967 cr | 40.6x | 24.4x | 48.9% | 66.5% | 0.00 | 27.6% | +20.8% | 2.10% |
| EMCURE Emcure Pharmaceuticals Limited | 44,481 cr | 40.7x | 8.3x | 19.6% | 24.8% | 0.27 | 10.7% | +24.3% | 0.15% |
| AJANTPHARM Ajanta Pharma Limited | 40,865 cr | 32.4x | 8.4x | 25.4% | 32.7% | 0.02 | 20.3% | +32.5% | 0.98% |
| SAILIFE Sai Life Sciences Limited | 37,985 cr | 100.5x | 14.1x | 15.1% | 20.9% | 0.17 | 15.9% | +22.5% | 0.00% |
| WOCKPHARMA Wockhardt Limited | 35,537 cr | 86.7x | 6.9x | 4.0% | 6.5% | 0.39 | 10.8% | +23.9% | 0.00% |
| ACUTAAS Acutaas Chemicals Limited | 32,561 cr | 74.1x | 17.5x | 23.5% | 31.7% | 0.00 | 27.5% | +42.7% | 0.06% |
| PPLPHARMA Piramal Pharma Limited | 31,906 cr | - | 3.9x | -4.0% | 0.8% | 0.69 | -2.1% | +28.1% | 0.00% |
| RUBICON Rubicon Research Limited | 28,510 cr | 87.3x | 20.1x | 19.1% | 23.4% | 0.28 | 15.5% | +39.9% | 0.09% |
| NEULANDLAB Neuland Laboratories Limited | 27,074 cr | 59.8x | 13.3x | 21.4% | 27.5% | 0.17 | 19.6% | -12.6% | 0.16% |
| APLLTD Alembic Pharmaceuticals Limited | 20,631 cr | 24.4x | 3.5x | 12.4% | 11.7% | 0.25 | 9.9% | +36.3% | 1.14% |
| GRANULES Granules India Limited | 19,853 cr | 27.7x | 3.0x | 13.5% | 15.7% | 0.09 | 12.1% | +20.3% | 0.22% |
| ERIS Eris Lifesciences Limited | 18,418 cr | 25.8x | 4.4x | 18.1% | 13.9% | 0.58 | 21.6% | +12.6% | 0.54% |
| ONESOURCE Onesource Specialty Pharma Limited | 18,381 cr | - | 3.1x | -1.3% | 0.4% | 0.25 | -0.1% | +37.4% | 0.00% |
| ALIVUS Alivus Life Sciences Limited | 17,801 cr | 26.6x | 4.9x | 18.4% | 24.6% | 0.00 | 24.9% | +16.0% | 0.34% |
| SHILPAMED Shilpa Medicare Limited | 17,616 cr | 52.7x | 6.4x | 9.8% | 11.4% | 0.24 | 18.1% | +43.0% | 0.07% |
| PFIZER Pfizer Limited | 17,614 cr | 20.5x | 4.0x | 17.2% | 23.4% | 0.00 | 32.4% | +13.2% | 1.95% |
| COHANCE Cohance Lifesciences Limited | 17,578 cr | 510.5x | 4.5x | 5.1% | 8.0% | 0.06 | -0.3% | -14.2% | 0.00% |
| NATCOPHARM Natco Pharma Limited | 16,124 cr | 17.8x | 1.6x | 16.9% | 17.1% | 0.11 | 26.9% | -29.0% | 0.70% |
| CAPLIPOINT Caplin Point Laboratories Limited | 15,845 cr | 23.0x | 4.1x | 19.9% | 24.7% | 0.00 | 29.4% | +17.9% | 0.38% |
| ASTRAZEN AstraZeneca Pharma India Limited | 15,283 cr | 86.0x | 17.4x | 22.8% | 31.2% | 0.00 | 6.8% | +30.4% | 0.59% |
| JUBLPHARMA Jubilant Pharmova Limited | 14,865 cr | 56.2x | 2.1x | 6.0% | 8.7% | 0.54 | 2.9% | +20.5% | 0.54% |
| CORONA CORONA Remedies Limited | 13,680 cr | 66.1x | 17.0x | 24.8% | 27.8% | 0.12 | 13.3% | +22.2% | 0.45% |
| MARKSANS Marksans Pharma Limited | 13,556 cr | 24.2x | 4.1x | 25.4% | 35.1% | 0.01 | 16.7% | +30.5% | 0.30% |
| CONCORDBIO Concord Biotech Limited | 11,642 cr | 41.6x | 5.6x | 13.5% | 17.9% | 0.00 | 23.9% | +25.1% | 0.68% |
Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.
Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.
Month by month| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.4 | -1.5 | -13.7 | +18.7 | +45.6 | -4.4 | +0.9 | -3.9 | +12.3 | -10.2 | +15.0 | · | +51.2% 11m |
| 2025 | +0.0 | -18.4 | +23.3 | -9.0 | +13.0 | +17.0 | -2.7 | -14.4 | +6.2 | -15.5 | -3.6 | +17.1 | +2.1% |
| 2024 | +8.5 | +31.3 | -3.0 | -3.3 | -6.5 | +29.7 | +34.4 | +13.9 | -6.9 | +23.5 | +16.2 | +0.9 | +233.9% |
| 2023 | -7.6 | -9.2 | -17.8 | +9.8 | -0.3 | +39.6 | +1.3 | -0.3 | -1.1 | -3.6 | +52.3 | +22.9 | +90.2% |
| 2022 | -4.6 | -13.9 | -15.6 | +4.5 | -6.2 | -19.3 | +6.0 | +9.0 | +1.3 | -4.3 | +1.9 | -6.2 | -41.4% |
| 2021 | -12.0 | +4.2 | -17.4 | +24.3 | +26.4 | -20.4 | +2.1 | -23.4 | +12.2 | -6.1 | +2.0 | -5.2 | -24.4% |
| 2020 | +51.0 | -13.0 | -43.8 | +48.1 | -15.5 | +30.0 | -1.7 | +13.3 | -5.8 | -1.1 | +55.5 | +20.7 | +133.6% |
| 2019 | -15.6 | -10.3 | +11.9 | -6.8 | -5.6 | -3.9 | -16.8 | -21.5 | +4.7 | +12.0 | -10.2 | -9.2 | -55.3% |
| 2018 | -13.6 | +1.9 | -11.4 | +14.7 | -18.0 | -6.2 | -8.2 | +12.9 | -18.4 | -8.8 | +9.7 | -3.5 | -43.8% |
| 2017 | -1.6 | +16.2 | -4.4 | -0.1 | -13.8 | -2.5 | +0.5 | -1.1 | +2.5 | +5.2 | +11.3 | +29.3 | +41.6% |
Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.
Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.
| Date | Party | Side | Quantity | Price | Value |
|---|---|---|---|---|---|
| 2024-01-01 | GRAVITON RESEARCH CAPITAL LLP · bulk | SELL | 8,44,583 | ₹456.72 | ₹38.57 Cr |
| 2024-01-01 | GRAVITON RESEARCH CAPITAL LLP · bulk | BUY | 8,44,583 | ₹456.76 | ₹38.58 Cr |
| 2023-12-12 | GRAVITON RESEARCH CAPITAL LLP · bulk | SELL | 9,79,549 | ₹397.26 | ₹38.91 Cr |
| 2023-12-12 | GRAVITON RESEARCH CAPITAL LLP · bulk | BUY | 9,79,549 | ₹397.13 | ₹38.90 Cr |
| 2023-12-11 | GRAVITON RESEARCH CAPITAL LLP · bulk | SELL | 9,16,319 | ₹372.83 | ₹34.16 Cr |
| 2023-12-11 | GRAVITON RESEARCH CAPITAL LLP · bulk | BUY | 9,16,319 | ₹373.22 | ₹34.20 Cr |
| 2023-11-17 | GRAVITON RESEARCH CAPITAL LLP · bulk | SELL | 11,48,101 | ₹325.17 | ₹37.33 Cr |
| 2023-11-17 | GRAVITON RESEARCH CAPITAL LLP · bulk | BUY | 11,48,101 | ₹324.81 | ₹37.29 Cr |
- Press releasePress Release2 Nov 2026
Wockhardt Limited has informed the Exchange regarding a press release dated November 02, 2026, titled "Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th...
- Board outcomeOutcome of Board Meeting2 Nov 2026
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no: WOCK/SEC/SE/2026-27/042 dated 27th October, 2026, we wish to inform you that the...
- Press releasePress Release10 Aug 2026
Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on theUnaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026.
- Board outcomeOutcome of Board Meeting10 Aug 2026
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no: WOCK/SEC/SE/2026-27/027 dated 4th August, 2026, we wish to inform you that the...
- Press releasePress Release4 May 2026
Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on theAudited Financial Results (Standalone and Consolidated) for the quarter and the financial yearended 31st March, 2026.
- Board outcomeOutcome of Board Meeting4 May 2026
Pursuant to Regulation 30 and 33 of Listing Regulations read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no. Ref. No.:...
- Board outcomeOutcome of Board Meeting4 May 2026
Pursuant to Regulation 30 and 33 of Listing Regulations read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no. Ref. No.:...
- Press releasePress Release10 Feb 2026
Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31st December, 2025.
- Board outcomeOutcome of Board Meeting10 Feb 2026
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no: WOCK/SEC/SE/2025-26/065 dated 4th February, 2026, we wish to inform you that the...
- Board outcomeOutcome of Board Meeting3 Nov 2025
Wockhardt Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
- Press releasePress Release8 Aug 2025
Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2025.
- Board outcomeOutcome of Board Meeting8 Aug 2025
Wockhardt Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
- Press releasePress Release29 May 2025
Wockhardt Limited has informed the Exchange regarding a press release dated May 29, 2025, titled "Press Release on the Audited Financial Results (Standalone and Consolidated) for the quarter and the financial year ended 31st March, 2025".
- Board outcomeOutcome of Board Meeting29 May 2025
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); please find enclosed herewith outcome of the board meeting held today i.e. May 29, 2025 along with Audited Standalone and Consolidated...
- Integrated Filing- Financial7 Feb 2025
Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2nd January, 2025, we are submitting herewith the Integrated Filing (Financial) for the quarter and nine-months ended 31st...
- Press releasePress Release7 Feb 2025
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31st December, 2024
- Financial Result Updates7 Feb 2025
Wockhardt Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.
Read enough? Test WOCKPHARMA. “Buy WOCKPHARMA when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.
Run it free